Enlivex Receives Positive Dsmb Recommendation And Imoh Clearance To Continue Phase I/Ii Trial Of Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers

March 20 (Reuters) - Enlivex Therapeutics Ltd: * ENLIVEX RECEIVES POSITIVE DSMB RECOMMENDATION AND IMOH CLEARANCE TO CONTINUE PHASE I/II TRIAL OF ALLOCETRA COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH

Moonlake Immunotherapeutics Reports Fourth Quarter And Year-End 2022 Financial Results And Provides A Business Update

March 20 (Reuters) - Moonlake Immunotherapeutics : * REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE * TOP-LINE RESULTS FOR A PHASE 2 TRIAL OF SONELOKIMAB IN

One Glove Group Proposes To Undertake Renounceable Rights Issue Of 142 Million New Shares

March 20 (Reuters) - One Glove Group Bhd: * PROPOSES TO UNDERTAKE REVISED RENOUNCEABLE RIGHTS ISSUE OF 142 MILLION NEW SHARES AT ISSUE PRICE OF 0.22 RGT PER SHARE * REVISED ISSUANCE ON BASIS OF 1

Orion's Darolutamide Approved For Additional Prostate Cancer Indication In China

March 20 (Reuters) - Orion Oyj: * DAROLUTAMIDE APPROVED FOR ADDITIONAL PROSTATE CANCER INDICATION IN CHINA * DAROLUTAMIDE IS ALREADY APPROVED IN CHINA FOR TREATMENT OF PATIENTS WITH NON-METASTATIC

Fonet Bilgi Teknolojileri Wins Tender Worth 5.9 Mln Lira From Tunceli Provincial Health Directorate

March 20 (Reuters) - Fonet Bilgi Teknolojileri AS : * FONET BILGI TEKNOLOJILERI AS WINS TENDER WORTH 5.9 MILLION LIRA FROM TUNCELI PROVINCIAL HEALTH DIRECTORATE Source text for Eikon: Further company

Hikma Says Launches Cefazolin For Injection, USP, In The US

March 20 (Reuters) - Hikma Pharmaceuticals PLC: * HIKMA - HIKMA LAUNCHES CEFAZOLIN FOR INJECTION, USP, IN THE US Further company coverage:

Cochlear, Demant contest UK regulator's Oticon deal concerns

March 20 (Reuters) - The UK's anti-trust regulator said on Monday that hearing device maker Cochlear and Copenhagen-based Demant had denied that the Australian firm's purchase of Demant's hearing

UK's CMA Says Demant,Cochlear Believe No Realistic Prospect Of Substantial Lessening Of Competition From Deal

March 20 (Reuters) - UK CMA: * UK'S CMA - DEMANT, COCHLEAR CONTEST CMA'S PHASE 1 FINDINGS THAT OTHER HEARING SOLUTIONS ARE NOT GOOD ALTERNATIVES FOR BONE CONDUCTION IMPLANTS * CMA - DEMANT, COCHLEAR

Switzerland wakes to new era after historic bank merger; employees 'shocked'

(Adds graphic, politician, academic) By Tom Sims and John Revill ZURICH, March 20 (Reuters) - Switzerland awoke to a new era on Monday after UBS swept up Credit Suisse in a government-brokered rescue

New Zealand foreign minister to meet Chinese counterpart in Beijing

(Adds comment from Chinese ministry) March 20 (Reuters) - New Zealand's foreign minister, Nanaia Mahuta, will travel to China on Tuesday to meet her counterpart Qin Gang on the first such visit by a